Problems encountered during anti-tumour necrosis factor therapy.

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• Tumour necrosis factor (TNF)-alpha antagonists are widely used for autoimmune and inflammatory diseases.
• Over 400,000 patients globally have received these therapies for conditions like rheumatoid arthritis and inflammatory bowel disease.
• Concerns regarding the safety profile of TNF-alpha antagonists have been raised since their approval.

Purpose of the Study:

• To review the safety profile and adverse events associated with TNF-alpha antagonists.
• To discuss the risks of re-activation of granulomatous diseases, particularly tuberculosis.
• To evaluate the impact of TNF-alpha antagonists on viral hepatitis, malignancy, and cardiovascular health.

Main Methods:

• Review of published data, case reports, package inserts, and postmarketing surveillance systems.
• Analysis of data from major rheumatology congresses (ACR and EULAR) from 2005.
• Focus on three commercially available TNF-alpha antagonists: etanercept, infliximab, and adalimumab.

Main Results:

• Risk of tuberculosis reactivation necessitates screening and treatment of latent infections.
• Hepatitis B reactivation can occur without concurrent antiviral therapy; hepatitis C appears safe.
• No increased risk of solid tumors; lymphoma risk is comparable to rheumatoid arthritis patients, not the general population.
• Adverse events include autoantibody formation, rare cases of aplastic anemia, pancytopenia, vasculitis, and demyelination.
• TNF-alpha antagonists are associated with worse prognosis in advanced heart failure and should be avoided.

Conclusions:

• TNF-alpha antagonists have a complex safety profile requiring careful patient selection and monitoring.
• Management of pre-existing conditions like tuberculosis and hepatitis B is crucial.
• While generally safe for solid tumors, careful consideration of cardiac status and potential hematologic/neurologic risks is warranted.